Peptide Stack Analyzer Tool Peptide Directory Peptide Discussion Forum Peptide Tools: Stacker & Calculators Trusted Vendors + Vendor Red Flags
Labels

Tesamorelin Peptide: Dosage, Protocol, Reconstitution, and Fat Loss Guide

Tesamorelin Peptide

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the body's natural growth hormone release pathway and increases IGF-1 levels. It is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy and has also been studied for effects on metabolism and body composition.

How Tesamorelin Works

GHRH → Growth Hormone ↑ → IGF-1 ↑ → Lipolysis ↑ → Visceral Fat ↓

This increases IGF-1 signaling and influences pathways involved in fat metabolism and body composition. Tesamorelin stimulates the GH axis rather than directly replacing growth hormone.

Tesamorelin is a GHRH analog, meaning it signals the pituitary to release growth hormone naturally.
It is best known for visceral fat reduction, especially in clinical HIV-associated lipodystrophy research and treatment settings.
It increases IGF-1 signaling and has been studied for effects on visceral fat reduction and body composition.
Because it can affect glucose and fluid balance, monitoring is important during longer cycles.
Tesamorelin Research Protocol
10 mg vial + 3.0 mL BAC Water → 1 unit = 33.3 mcg → Visceral Fat + GH Support
Standard Setup
Vial 10 mg
Water 3.0 mL bacteriostatic water
Concentration 3.33 mg/mL
Conversion 1 unit = 33.3 mcg
Week 1
Start Phase
Dose1 mg (1000 mcg)
Units30 units
Volume0.30 mL
Weeks 2+
Clinical Dose Range
Dose2 mg (2000 mcg)
Units60 units
Volume0.60 mL
Protocol Details
FrequencyOnce daily
TimingEvening
Cycle Length12–26 weeks
Clinical DurationUp to 52 weeks in clinical settings
Simple structure
Tesamorelin is usually discussed as a longer metabolic and body-composition protocol. Short runs may not be enough to fully evaluate visceral fat changes, so tracking over time matters.
Dosing Notes
Some protocols evaluate lower initial exposure before reaching the studied 2 mg daily dose
Start at 1 mg to assess tolerance
Increase to 2 mg for the full protocol target
Evening dosing may better align with natural GH rhythm
Longer study durations have provided more data on visceral fat changes
Monitor glucose, fluid retention, and joint symptoms during longer use
How to Use Tesamorelin (Timing & Injection)
Injection TypeSubcutaneous
Common SiteAbdomen
TimingEvening, consistent time daily
Use StyleMetabolic / visceral fat protocol
When & Where to Inject
Inject subcutaneously in the abdomen
Avoid the area within 2 inches of the navel
Rotate injection sites daily
Inject at a consistent time each evening
Avoid irritated, bruised, scarred, or hardened areas
Timing Notes
Evening use is commonly discussed because GH release naturally rises during sleep.
Consistent daily timing helps make response and side effects easier to track.
Tesamorelin works best as part of a structured metabolic plan, not as a quick fat-loss shortcut.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water3.0 mL bacteriostatic
Concentration3.33 mg/mL
Conversion1 unit = 33.3 mcg
Dose Reference
30 units = 1 mg (1000 mcg)
60 units = 2 mg (2000 mcg)
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Ensure solution is clear
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C / 35–46°F
Long-term storage: freezing at −20°C / −4°F is commonly preferred
Estimated refrigerated shelf life: commonly ~12–24 months when sealed, dry, and protected from light
Estimated frozen shelf life: commonly up to ~2–3 years when stored properly
Keep sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Do not repeatedly freeze and thaw the same vial
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C / 36–46°F
Use within 7 days after reconstitution
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Tesamorelin should be kept cold and protected from light. Once mixed, it has a shorter use window than many peptides, so label the vial with the mix date and use within the stated window.
Cycle Length & Time Between Cycles
Visceral Fat Phase → Monitor IGF-1 + Glucose → Reassess → Continue or Break
Standard Cycle Structure
Cycle Length12–26 weeks
Clinical DurationUp to 52 weeks
Primary GoalVisceral fat reduction + IGF-1 support
Use StyleLonger metabolic protocol
Time Between Cycles
Break4–8 weeks after longer cycles
Allows IGF-1, glucose, and fluid balance to be reassessed
Helps determine whether visceral fat changes are maintained
Gives time to evaluate whether continued therapy is still appropriate
No standardized evidence-based "off cycle" has been established. Reassessment is based on treatment goals, response, glucose markers, IGF-1 levels, and tolerability
Why cycle?
Tesamorelin has been studied in longer-duration protocols. Reassessment helps evaluate body-composition changes, metabolic markers, tolerability, and whether continued use remains appropriate.
Monitoring During Use
IGF-1 levels, key biomarker
Body composition and visceral fat changes
Blood glucose and HbA1c
Lipid profile
Fluid retention or edema
Joint discomfort or carpal tunnel-like symptoms
Benefits
Reduces visceral abdominal fat
Increases natural growth hormone levels
Improves IGF-1 signaling
Supports metabolic health
May support liver fat reduction in NAFLD-related discussions
Preserves lean muscle mass
Potential Side Effects
Injection site irritation
Water retention
Joint stiffness or discomfort
Mild increase in blood glucose
Carpal tunnel-like symptoms, rare
Possible IGF-1 elevation beyond target range if not monitored
Stacking Strategies
Visceral Fat Support → Metabolic Pairing → Monitor Glucose + IGF-1
Common Pairing Approaches
Fat Loss: Tesamorelin + GLP-1 (Tirzepatide / Semaglutide)
Advanced: Tesamorelin + Ipamorelin
Metabolic: Tesamorelin + NAD+
What to Avoid
Stacking multiple GH-pathway peptides without IGF-1 monitoring
Ignoring glucose changes when combining with metabolic compounds
Using without a nutrition, protein, and resistance-training plan
Simple rule
Tesamorelin is already a strong metabolic GH-pathway peptide. Stacking should focus on a clear goal, usually visceral fat, metabolic support, or body composition, while monitoring glucose and IGF-1 response.
Important Notes
FDA-approved for HIV-associated lipodystrophy
Most associated with visceral fat reduction
Longer cycles produce clearer body-composition outcomes
Glucose and IGF-1 monitoring matter during use
Not the same as general weight-loss medication
Works best with structured nutrition and training support

Important Disclaimer

Tesamorelin is FDA-approved for specific medical use but should only be used under medical supervision. This content is for educational purposes only.

Research & References

Primary Research

Research Note: Tesamorelin is FDA-approved (as Egrifta) specifically for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. Use outside this approved indication is investigational and less well-studied.
Tesamorelin Guide → Peptide Directory →
Email Post
Similar Links:

Comments

Post a Comment